Dexamethasone doses in patients with COVID‐19 and hypoxia: A systematic review and meta‐analysis
MW Munch, A Granholm, J Maláska… - Acta …, 2024 - Wiley Online Library
Background The optimal dose of dexamethasone for severe/critical COVID‐19 is uncertain.
We compared higher versus standard doses of dexamethasone in adults with COVID‐19 …
We compared higher versus standard doses of dexamethasone in adults with COVID‐19 …
Corticosteroids in adults with acute respiratory distress syndrome and severe pneumonia
D Jayasimhan, MA Matthay - BJA education, 2023 - bjaed.org
Discuss the pathogenesis of ARDS and the rationale for corticosteroid treatment. Evaluate
the evidence for the use of corticosteroids in specific subgroups of adults with ARDS. Apply …
the evidence for the use of corticosteroids in specific subgroups of adults with ARDS. Apply …
Outcomes of different steroid dosing regimens in critical Covid-19 pneumonia at a Kenyan hospital: A retrospective cohort study
JO Odhiambo, J Shah, N Kunyiha, C Makasa, F Riunga - Plos one, 2024 - journals.plos.org
Background Among therapeutic options for severe and critical COVID-19 infection,
dexamethasone six milligrams once daily for ten days has demonstrated mortality benefit …
dexamethasone six milligrams once daily for ten days has demonstrated mortality benefit …
Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review
Importance Severe pulmonary infections, including COVID-19, community-acquired
pneumonia, influenza, andPneumocystispneumonia, are a leading cause of death among …
pneumonia, influenza, andPneumocystispneumonia, are a leading cause of death among …
Heterogeneity, Bayesian thinking, and phenotyping in critical care: A primer
TW Jones, T Hendrick, AM Chase - American Journal of Health …, 2024 - academic.oup.com
Purpose To familiarize clinicians with the emerging concepts in critical care research of
Bayesian thinking and personalized medicine through phenotyping and explain their clinical …
Bayesian thinking and personalized medicine through phenotyping and explain their clinical …
Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19
F Salton, P Confalonieri, C Torregiani… - Annals of the …, 2023 - atsjournals.org
We read with interest the study from Pitre et al., who systematically reviewed 20 randomized
controlled trials (RCTs) published through August 2022, concluding that higher doses of …
controlled trials (RCTs) published through August 2022, concluding that higher doses of …
Back to the Future: A Case of Severe ARDS Responsive to Shunned Therapies, A Review of the Past, and a Road Map to Future Investigations
P Keith, C Choe, B Rikard, K Stoudemire… - Intensive Care …, 2024 - Springer
Background The COVID-19 pandemic served as a reminder of the limited treatments
available for acute respiratory distress syndrome (ARDS). The pandemic has highlighted the …
available for acute respiratory distress syndrome (ARDS). The pandemic has highlighted the …
Reply: Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19
T Pitre, D Zeraatkar - Annals of the American Thoracic Society, 2023 - atsjournals.org
With regards to patients who may benefit from corticosteroids, the landscape is changing
rapidly as patients are now most often vaccinated and receive additional …
rapidly as patients are now most often vaccinated and receive additional …